<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>前沿研究_鼓舞援助</title><link>http://www.guwu.ren/exhibit/</link><pubDate>2026-04-21 18:49:06</pubDate><item id="200"><title><![CDATA[NTRK突变实体瘤患者|靶向治疗]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-200.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 16:52:44</pubDate></item><item id="199"><title><![CDATA[复发/难治性淋巴瘤患者| PI3Kδ]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-199.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 16:49:47</pubDate></item><item id="198"><title><![CDATA[B细胞非霍奇金淋巴瘤|CAR-T]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-198.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 16:11:25</pubDate></item><item id="197"><title><![CDATA[晚期或复发性子宫内膜癌|PD-1联合靶向治疗]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-197.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 16:08:58</pubDate></item><item id="196"><title><![CDATA[BRCA突变卵巢癌患者|PARP抑制剂]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-196.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 16:05:41</pubDate></item><item id="195"><title><![CDATA[HER-2阳性乳腺癌患者]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-195.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 16:02:45</pubDate></item><item id="194"><title><![CDATA[HR+/HER2-早期乳腺癌|CDK4/6辅助治疗]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-194.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 15:56:10</pubDate></item><item id="193"><title><![CDATA[ER+/HER2-的晚期乳腺癌|CDK4/6联合内分泌治疗]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-193.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 15:39:51</pubDate></item><item id="192"><title><![CDATA[招募HER2+乳腺癌患者|HER2靶向治疗（赫赛汀）]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-192.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 15:35:53</pubDate></item><item id="191"><title><![CDATA[招募三阴乳腺癌患者|PD-L1联合化疗]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-191.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 15:06:49</pubDate></item><item id="190"><title><![CDATA[招募HER2阳性复发/转移性乳腺癌患者|HER2靶向治疗]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-190.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 15:00:23</pubDate></item><item id="189"><title><![CDATA[招募HR+/HER2-乳腺癌患者|CDK4/6抑制剂]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-189.html</link><description><![CDATA[]]></description><pubDate>2021-01-12 14:52:14</pubDate></item><item id="188"><title><![CDATA[晚期一线肝细胞癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-188.html</link><description><![CDATA[]]></description><pubDate>2020-06-08 12:16:46</pubDate></item><item id="187"><title><![CDATA[L015 胶囊治疗NTRK基因融合的晚期恶性实体瘤患者]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-187.html</link><description><![CDATA[]]></description><pubDate>2019-11-07 10:40:05</pubDate></item><item id="186"><title><![CDATA[【实体瘤L014】免疫治疗局部晚期或转移性实体瘤]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-186.html</link><description><![CDATA[]]></description><pubDate>2019-11-07 10:38:05</pubDate></item><item id="185"><title><![CDATA[L16  M701治疗恶性腹水的I期临床试验]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-185.html</link><description><![CDATA[]]></description><pubDate>2019-11-07 10:34:41</pubDate></item><item id="184"><title><![CDATA[L19 免疫治疗晚期恶性肿瘤（高级别（G3）神经内分泌肿瘤）]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-184.html</link><description><![CDATA[]]></description><pubDate>2019-11-07 10:32:45</pubDate></item><item id="183"><title><![CDATA[ANGE-S001治疗小儿脑瘫的单中心随机安慰剂平行对照]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-183.html</link><description><![CDATA[]]></description><pubDate>2019-11-04 17:52:10</pubDate></item><item id="181"><title><![CDATA[【实体瘤A012】免疫治疗晚期实体瘤]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-181.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:40:20</pubDate></item><item id="180"><title><![CDATA[实体瘤A008 小分子Na+/K+-ATP酶抑制剂抗肿瘤新药]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-180.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:39:13</pubDate></item><item id="179"><title><![CDATA[【实体瘤A011】免疫治疗晚期实体瘤]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-179.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:38:02</pubDate></item><item id="178"><title><![CDATA[【胃癌A009】免疫一线，胃癌或胃食管交界处癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-178.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:36:10</pubDate></item><item id="177"><title><![CDATA[【食管癌A009】靶向治疗食管鳞癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-177.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:34:55</pubDate></item><item id="176"><title><![CDATA[肝癌A015 Pexa-Vec牛痘病毒一线治疗晚期肝细胞癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-176.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:33:34</pubDate></item><item id="175"><title><![CDATA[【肺癌A040】免疫一线，非小细胞肺癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-175.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:31:26</pubDate></item><item id="174"><title><![CDATA[【食管癌A008】免疫一线，食管鳞癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-174.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:30:16</pubDate></item><item id="173"><title><![CDATA[【尿路上皮癌A004】免疫一线，膀胱癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-173.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:29:13</pubDate></item><item id="172"><title><![CDATA[A026免疫，EB病毒阳性的结外NK/T细胞/弥漫性大B细胞]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-172.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:27:03</pubDate></item><item id="171"><title><![CDATA[【骨髓瘤A025】靶向一线治疗多发性骨髓瘤]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-171.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:22:35</pubDate></item><item id="170"><title><![CDATA[A024 靶向二线及以上复发惰性CD20阳性B细胞非霍奇金]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-170.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:18:49</pubDate></item><item id="169"><title><![CDATA[【鼻咽癌A005】免疫一线，复发或转移性鼻咽癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-169.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:16:31</pubDate></item><item id="168"><title><![CDATA[【实体瘤A010】靶向联合免疫治疗晚期实体瘤（非小细胞肺癌）]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-168.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:11:44</pubDate></item><item id="167"><title><![CDATA[A009靶向联合免疫治疗晚期实体瘤 肝癌胃或胃食管结合部腺癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-167.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:10:22</pubDate></item><item id="166"><title><![CDATA[【肺癌A039】标准化疗治疗鳞状细胞非小细胞肺癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-166.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:07:21</pubDate></item><item id="165"><title><![CDATA[【肺癌A038】靶向治疗晚期非小细胞肺癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-165.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:04:43</pubDate></item><item id="164"><title><![CDATA[【头颈部癌A003】靶向一线，头颈部鳞状细胞癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-164.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 19:01:06</pubDate></item><item id="163"><title><![CDATA[A037 靶向治疗EGFR罕见突变的非小细胞肺癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-163.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:59:49</pubDate></item><item id="162"><title><![CDATA[【实体瘤A007】靶向治疗实体瘤]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-162.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:58:10</pubDate></item><item id="161"><title><![CDATA[【卵巢癌A005】靶向三线及以上，BRCA 突变卵巢癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-161.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:56:20</pubDate></item><item id="160"><title><![CDATA[【淋巴瘤A023】靶向治疗CD20阳性B细胞非霍奇金淋巴瘤]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-160.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:54:47</pubDate></item><item id="159"><title><![CDATA[【实体瘤A006】CAR-T 细胞治疗晚期实体瘤]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-159.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:51:04</pubDate></item><item id="158"><title><![CDATA[【骨髓瘤A022】靶向三线，难治性或复发性多发性骨髓瘤]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-158.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:49:36</pubDate></item><item id="157"><title><![CDATA[【鼻咽癌A004】免疫一线，复发或转移性鼻咽癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-157.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:48:34</pubDate></item><item id="156"><title><![CDATA[【前列腺癌A002】一线，去势抵抗性前列腺癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-156.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:47:15</pubDate></item><item id="155"><title><![CDATA[【肝癌A014】免疫联合靶向一线，晚期肝细胞癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-155.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:45:56</pubDate></item><item id="154"><title><![CDATA[【食管癌A006】靶向二线及以上，晚期食管鳞癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-154.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:44:33</pubDate></item><item id="153"><title><![CDATA[【胸腺癌A003】靶向二线及以上，晚期复发或转移性胸腺癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-153.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:43:09</pubDate></item><item id="152"><title><![CDATA[【肺癌A035】靶向三线及以上，晚期鳞状非小细胞肺癌]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-152.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:38:42</pubDate></item><item id="151"><title><![CDATA[【贫血A004】重组人促红素注射液治疗化疗引起的贫血]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-151.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:30:08</pubDate></item><item id="150"><title><![CDATA[【淋巴瘤A021】淋巴瘤米托蒽醌脂质体化疗]]></title><link>http://www.guwu.ren/exhibit/show-htm-itemid-150.html</link><description><![CDATA[]]></description><pubDate>2019-07-14 18:25:24</pubDate></item></channel></rss>